All In Biotech

Drug Trial Radar · NCT03948646

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)

A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis

Last checked: Nov 20, 2026Latest source record: May 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 351 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

351

Actual

Start

Dec 4, 2020

Primary completion

Aug 13, 2021

Study completion Aug 13, 2021

Sponsor

Lead sponsor
Botanix PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Current therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 3 study will assess the safety and efficacy of sofpironium bromide, 15% gel versus vehicle (2 treatment arms), applied for the treatment of axillary hyperhidrosis.

Conditions

  • Axillary Hyperhidrosis

Interventions

  • Sofpironium Bromide, 15%Drug

    Active

  • VehicleDrug

    Vehicle gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity Measure-Axillary-7 Item Total Score From Baseline to End of TreatmentTime frame: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.
  2. Observed Change in Participant (Vehicle Arm vs SB Gel 15% Arm) Ranked Gravimetric Sweat Production From Baseline to End of TreatmentTime frame: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Cahaba Dermatology Skin & Health Center

    Birmingham, Alabama

  • Advanced Research Associates

    Glendale, Arizona

  • Arkansas Research Trials

    North Little Rock, Arkansas

  • First OC Dermatology

    Fountain Valley, California

  • CoDerm Research

    Centennial, Colorado

  • Colorado Medical Research Center

    Denver, Colorado

  • CCD Research, PLLC

    Cromwell, Connecticut

  • The GW Medical Faculty Associates

    Washington D.C., District of Columbia

  • Driven Research, LLC

    Coral Gables, Florida

  • Florida Academic Dermatology Centers Research & Education, LLC

    Coral Gables, Florida

  • GSI Clinical Research

    Margate, Florida

  • Cordova Research Institute

    Miami, Florida

  • MOORE Clinical Research, Inc.

    Tampa, Florida

  • Advanced Medical Research PC

    Sandy Springs, Georgia

  • DeNova Research

    Chicago, Illinois

  • Qualmedica Research, LLC

    Evansville, Indiana

  • Heartland Research Asssociates - AMR Company

    Wichita, Kansas

  • Delricht Research

    Baton Rouge, Louisiana

  • DelRicht Research

    New Orleans, Louisiana

  • Lupo Center for Aesthetic and General Dermatology

    New Orleans, Louisiana

  • Etre, Cosmetic Dermatology and Laser Center

    New Orleans, Louisiana

  • DermAssociates

    Rockville, Maryland

  • Bay State Clinical Trials, Inc.

    Watertown, Massachusetts

  • Michigan Center for Skin Care Research

    Clinton Township, Michigan

  • Hamzavi Dermatology, Inc.

    Fort Gratiot, Michigan

  • Saint Louis University, Department of Dermatology

    St Louis, Missouri

  • Meridian Clinical Research, LLC

    Omaha, Nebraska

  • JDR Dermatology Research

    Las Vegas, Nevada

  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

  • SkinSearch of Rochester

    Rochester, New York

  • Dermatology, Laser and Vein Specialists of the Carolinas

    Charlotte, North Carolina

  • Aventiv Research Inc.

    Dublin, Ohio

  • Yardley Dermatology Associates, PC

    Morrisville, Pennsylvania

  • Westlake Dermatology & Cosmetic Surgery

    Austin, Texas

  • Bellaire Dermatology Associates

    Bellaire, Texas

  • J&S Studies, Inc.

    College Station, Texas

  • Modern Research Associates

    Dallas, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Suzanne Bruce and Associates, P.A.

    Houston, Texas

  • Dermatology Clinical Research Center of San Antonio

    San Antonio, Texas

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.